First Tracks Biotherapeutics (NASDAQ:TRAX) Stock Price Expected to Rise, Wedbush Analyst Says

First Tracks Biotherapeutics (NASDAQ:TRAX) had its price objective lifted by investment analysts at Wedbush from $30.00 to $60.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Wedbush’s target price suggests a potential upside of 42.76% from the company’s previous close.

Several other brokerages have also recently weighed in on TRAX. Leerink Partners started coverage on shares of First Tracks Biotherapeutics in a report on Friday, April 24th. They issued an “outperform” rating and a $46.00 target price on the stock. UBS Group started coverage on shares of First Tracks Biotherapeutics in a report on Tuesday, April 21st. They set a “buy” rating and a $45.00 price target for the company. Piper Sandler began coverage on shares of First Tracks Biotherapeutics in a research report on Monday, May 4th. They issued an “overweight” rating and a $54.00 price objective on the stock. Barclays increased their price objective on shares of First Tracks Biotherapeutics from $40.00 to $48.00 and gave the company an “overweight” rating in a research report on Tuesday, July 21st. Finally, HC Wainwright raised their price objective on shares of First Tracks Biotherapeutics from $30.00 to $44.00 and gave the company a “buy” rating in a report on Friday, July 10th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $47.88.

First Tracks Biotherapeutics Stock Up 18.3%

Shares of TRAX opened at $42.03 on Tuesday. The firm has a 50-day moving average of $22.37. The stock has a market cap of $1.47 billion and a PE ratio of -22.84. First Tracks Biotherapeutics has a 1 year low of $14.72 and a 1 year high of $46.45.